{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:26:03Z","timestamp":1789453563388,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.euroneuro.2017.02.005","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T16:32:17Z","timestamp":1488904337000},"page":"383-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clozapine as the most efficacious antipsychotic for activating ERK 1\/2 kinases: Role of 5-HT 2A receptor agonism"],"prefix":"10.1016","volume":"27","author":[{"given":"Stefano","family":"Aringhieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivakumar","family":"Kolachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gerace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Verdesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Brunacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Solini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni U.","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Scarselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.euroneuro.2017.02.005_bib1","first-page":"2018","article-title":"A signaling pathway AKTing up in schizophrenia","volume":"118","author":"Arguello","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.euroneuro.2017.02.005_bib2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1146\/annurev.pharmtox.011008.145634","article-title":"Akt\/GSK3 signaling in the action of psychotropic drugs","volume":"49","author":"Beaulieu","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.euroneuro.2017.02.005_bib3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.euroneuro.2014.12.002","article-title":"The atypical antipsychotic clozapine selectively inhibits interleukin 8 (IL-8)-induced neutrophil chemotaxis","volume":"25","author":"Capannolo","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.005_bib4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-pharmtox-010611-134609","article-title":"Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters","volume":"53","author":"Cheepala","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.euroneuro.2017.02.005_bib5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00213-002-1043-0","article-title":"Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors","volume":"162","author":"Cussac","year":"2002","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.euroneuro.2017.02.005_bib6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00418-014-1217-y","article-title":"Progress in quantitative single-molecule localization microscopy","volume":"142","author":"Deschout","year":"2014","journal-title":"Histochem. Cell. Biol."},{"key":"10.1016\/j.euroneuro.2017.02.005_bib7","first-page":"5","article-title":"AKT\/GSK3 signaling pathway and schizophrenia","volume":"15","author":"Emamian","year":"2012","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.euroneuro.2017.02.005_bib8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1176\/appi.ajp.2009.08121873","article-title":"Roles of the Akt\/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action","volume":"167","author":"Freyberg","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.02.005_bib9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","article-title":"Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs","volume":"147","author":"Fribourg","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.euroneuro.2017.02.005_bib10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1124\/mol.62.5.1094","article-title":"Beta(2)-adrenergic receptor lacking the cyclic AMP-dependent protein kinase consensus sites fully activates extracellular signal-regulated kinase 1\/2 in human embryonic kidney 293 cells: lack of evidence for G(s)\/G(i) switching","volume":"62","author":"Friedman","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2017.02.005_bib11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.euroneuro.2008.09.001","article-title":"Antipsychotic drugs modulate Arc expression in the rat brain","volume":"19","author":"Fumagalli","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2017.02.005_bib12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd2806","article-title":"The \u05f3atypicality\u05f3 of antipsychotics: a concept re-examined and re-defined","volume":"8","author":"Grunder","year":"2009","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"43","key":"10.1016\/j.euroneuro.2017.02.005_bib13","doi-asserted-by":"publisher","first-page":"22853","DOI":"10.1074\/jbc.A111.287433","article-title":"IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase\/PDK1\/mTORC2 and the pleckstrin homology domain to sustain malignant transformation","volume":"291","author":"Guo","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.euroneuro.2017.02.005_bib14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2478\/acph-2014-0036","article-title":"Therapeutic drug monitoring of atypical antipsychotic drugs","volume":"64","author":"Grundmann","year":"2014","journal-title":"Acta Pharm."},{"issue":"6","key":"10.1016\/j.euroneuro.2017.02.005_bib15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2017.02.005_bib16","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1176\/appi.ajp.161.6.985","article-title":"Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol","volume":"161","author":"Keefe","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2017.02.005_bib17","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/j.1476-5381.2011.01749.x","article-title":"Biased signalling and allosteric machines: new vistas and challenges for drug discovery","volume":"165","author":"Kenakin","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.005_bib18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0074-7742(04)59008-6","article-title":"Mitogen-activated protein kinase signaling","volume":"59","author":"Kyosseva","year":"2004","journal-title":"Int. Rev. Neurobiol."},{"issue":"10","key":"10.1016\/j.euroneuro.2017.02.005_bib19","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1523\/JNEUROSCI.5467-07.2008","article-title":"Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition","volume":"28","author":"Leng","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.02.005_bib20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.euroneuro.2017.02.005_bib21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/archpsyc.62.4.361","article-title":"Antipsychotic drug effects on brain morphology in first-episode psychosis","volume":"62","author":"Lieberman","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2017.02.005_bib22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1124\/pr.107.00107","article-title":"Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection","volume":"60","author":"Lieberman","year":"2008","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.euroneuro.2017.02.005_bib23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/FTD.0b013e3181aa4780","article-title":"Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response","volume":"31","author":"Lostia","year":"2009","journal-title":"Ther. Drug. Monit."},{"issue":"1","key":"10.1016\/j.euroneuro.2017.02.005_bib24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.brainres.2004.03.018","article-title":"Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt\/PKB, ERK1\/2, and the mitogen-activated protein kinase p38","volume":"1011","author":"Lu","year":"2004","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.euroneuro.2017.02.005_bib25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1385\/JMN:27:1:043","article-title":"Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K\/AKT, ERK, and pertussis toxin-sensitive pathways","volume":"27","author":"Lu","year":"2005","journal-title":"J. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.euroneuro.2017.02.005_bib26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.cell.2008.12.044","article-title":"Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta\/beta-catenin signaling","volume":"136","author":"Mao","year":"2009","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.euroneuro.2017.02.005_bib27","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.biopsych.2004.02.003","article-title":"Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain","volume":"55","author":"Maragnoli","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"36","key":"10.1016\/j.euroneuro.2017.02.005_bib28","doi-asserted-by":"publisher","first-page":"13656","DOI":"10.1073\/pnas.0803522105","article-title":"Antagonism of dopamine D2 receptor\/\u03b2-arrestin 2 interaction is a common property of clinically effective antipsychotics","volume":"105","author":"Masri","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.euroneuro.2017.02.005_bib29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.eurpsy.2004.09.009","article-title":"Clinical outcome and olanzapine plasma levels in acute schizophrenia","volume":"20","author":"Mauri","year":"2005","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2017.02.005_bib30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2017.02.005_bib31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.euroneuro.2017.02.005_bib32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2017.02.005_bib33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"issue":"12","key":"10.1016\/j.euroneuro.2017.02.005_bib34","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2017.02.005_bib35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pharmthera.2009.06.001","article-title":"Antipsychotic drug actions on gene modulation and signaling mechanisms","volume":"124","author":"Molteni","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.euroneuro.2017.02.005_bib36","doi-asserted-by":"publisher","first-page":"7476","DOI":"10.1074\/jbc.M306818200","article-title":"The paired activation of the two components of the muscarinic M3 receptor dimer is required for induction of ERK1\/2 phosphorylation","volume":"279","author":"Novi","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.euroneuro.2017.02.005_bib37","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.euroneuro.2008.12.012","article-title":"Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells","volume":"19","author":"Park","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.02.005_bib38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12031-009-9188-5","article-title":"Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor","volume":"39","author":"Pereira","year":"2009","journal-title":"J. Mol. Neurosci."},{"issue":"8","key":"10.1016\/j.euroneuro.2017.02.005_bib39","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1017\/S1461145711001404","article-title":"Clozapine induction of ERK1\/2 cell signaling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs","volume":"15","author":"Pereira","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2017.02.005_bib40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1046\/j.1471-4159.2003.01851.x","article-title":"Opposite regulation by typical and atypical anti-psychotics of ERK1\/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum","volume":"86","author":"Pozzi","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2017.02.005_bib41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev.pharmtox.010909.105800","article-title":"Molecular mechanism of \u03b2-arrestin-biased agonism at seven-transmembrane receptors","volume":"52","author":"Reiter","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.euroneuro.2017.02.005_bib42","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1158\/0008-5472.CAN-07-5783","article-title":"Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity","volume":"68","author":"Rhodes","year":"2008","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.euroneuro.2017.02.005_bib43","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0028-3908(99)00031-3","article-title":"Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine","volume":"38","author":"Riva","year":"1999","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.euroneuro.2017.02.005_bib44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1385\/MB:31:2:151","article-title":"The ERK cascade: a prototype of MAPK signaling","volume":"31","author":"Rubinfeld","year":"2005","journal-title":"Mol. Biotechnol."},{"issue":"27","key":"10.1016\/j.euroneuro.2017.02.005_bib45","doi-asserted-by":"publisher","first-page":"6983","DOI":"10.1523\/JNEUROSCI.0679-08.2008","article-title":"Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive Function","volume":"28","author":"Samuels","year":"2008","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.euroneuro.2017.02.005_bib46","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.neuron.2009.01.001","article-title":"MAP\u2019ing CNS development and cognition: an ERKsome process","volume":"61","author":"Samuels","year":"2009","journal-title":"Neuron"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2017.02.005_bib47","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ejphar.2008.02.003","article-title":"Different affinities of native alpha1B-adrenoceptors for ketanserin between intact tissue segments and membrane preparations","volume":"584","author":"Sathi","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2017.02.005_bib48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1042\/BST20120250","article-title":"Enlightening G-protein-coupled receptors on the plasma membrane using super-resolution photoactivated localization microscopy","volume":"41","author":"Scarselli","year":"2013","journal-title":"Biochem. Soc. Trans."},{"issue":"6","key":"10.1016\/j.euroneuro.2017.02.005_bib49","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1074\/jbc.M806819200","article-title":"Constitutive internalization of G protein-coupled receptors and G proteins via clathrin-independent endocytosis","volume":"284","author":"Scarselli","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.euroneuro.2017.02.005_bib50","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/npp.2014.38","article-title":"Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a \u03b2arrestin2-independent activation of Akt","volume":"39","author":"Schmid","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.02.005_bib51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0074-7742(09)85026-5","article-title":"Role of Akt and Erk signaling in the neurogenesis following brain ischemia","volume":"85","author":"Shioda","year":"2009","journal-title":"Int. Rev. Neurobiol."},{"issue":"4","key":"10.1016\/j.euroneuro.2017.02.005_bib52","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1176\/ajp.155.4.505","article-title":"Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PT study of chlorpromazine, clozapine, andamisulpride in schizophrenic patients","volume":"155","author":"Trichard","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.euroneuro.2017.02.005_bib53","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/sj.npp.1301347","article-title":"Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study","volume":"32","author":"Van Haren","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.02.005_bib54","doi-asserted-by":"publisher","first-page":"20033","DOI":"10.1038\/srep20033","article-title":"5-HT2 receptors mediate functional modulation of GABAa receptors and inhibitory synaptic transmissions in human iPS-derived neurons","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.euroneuro.2017.02.005_bib55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.brainres.2012.06.032","article-title":"The possible role of the Akt signaling pathway in schizophrenia","volume":"1470","author":"Zheng","year":"2012","journal-title":"Brain Res."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17301761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17301761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T19:50:31Z","timestamp":1536004231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17301761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0924977X17301761"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.02.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine as the most efficacious antipsychotic for activating ERK 1\/2 kinases: Role of 5-HT2A receptor agonism","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}